Global Central Precocious Puberty Cpp Treatment Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2022 –2029 |
 Taille du marché (année de référence) |
USD 1,482.52 Million |
 Taille du marché (année de prévision) |
USD 2,663.78 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché mondial du traitement de la puberté précoce centrale (CPP) , par type (médicaments, chirurgie ), diagnostic (analyses sanguines, IRM, tomodensitométries, radiographies), mois (1 mois, 2 mois, 6 mois, autres), voie d’administration (parentérale, implants, orale, autres), sexe (filles, garçons), utilisateurs finaux (hôpitaux, cliniques spécialisées, soins à domicile, autres), canal de distribution (pharmacie hospitalière, pharmacie de détail, pharmacie en ligne, autres) – Tendances et prévisions de l’industrie jusqu’en 2029.
Analyse et taille du marché
Ces dernières années, le marché du traitement de la puberté précoce centrale (CPP) devrait croître rapidement au cours de la période de prévision. Les agonistes de l'hormone de libération des gonadotrophines (GnRH) peuvent être utilisés pour traiter la CPP car ils bloquent les effets stimulants de la GnRH endogène et accélèrent le développement osseux, empêchant ainsi la puberté précoce. La ménarche est retardée lorsque le traitement à la GnRH est utilisé pour retarder le début de la puberté. Triptodor, Lupron Depot-Ped (acétate de leuprolide) et Supprelin LA (acétate d'histréline) sont trois médicaments thérapeutiques approuvés pour la puberté précoce centrale actuellement sur le marché (CPP).
Français Data Bridge Market Research analyse que le marché du traitement central de la puberté précoce (CPP) était évalué à 1 482,52 millions USD en 2021 et devrait atteindre 2 663,78 millions USD d'ici 2029, enregistrant un TCAC de 7,60 % au cours de la période de prévision de 2022 à 2029. Le rapport de marché organisé par l'équipe de recherche sur le marché Data Bridge comprend une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.
Définition du marché
La puberté précoce dépendante des gonadotrophines est appelée puberté précoce centrale (PPC). Il s'agit d'un trouble du développement lié au système endocrinien caractérisé par le début des changements pubertaires, des caractères sexuels secondaires, une croissance plus rapide et une maturation osseuse avant l'âge typique de la puberté (8 ans chez les filles et 9 ans chez les garçons). Il s'agit d'un trouble idiopathique. Cependant, les mutations du gène MKRN3 sont la cause génétique la plus courante connue de la puberté précoce centrale.
Portée du rapport et segmentation du marché
|
Rapport métrique |
Détails |
|
Période de prévision |
2022 à 2029 |
|
Année de base |
2021 |
|
Années historiques |
2020 (personnalisable de 2019 à 2014) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD, volumes en unités, prix en USD |
|
Segments couverts |
Type (médicament, chirurgie), diagnostic (analyses sanguines, IRM, tomodensitométrie, radiographies), mois (1 mois, 2 mois, 6 mois, autres), voie d'administration (parentérale, implants, orale, autres), sexe (filles, garçons), utilisateurs finaux (hôpitaux, cliniques spécialisées, soins à domicile, autres), canal de distribution (pharmacie hospitalière, pharmacie de détail, pharmacie en ligne, autres) |
|
Pays couverts |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Ireland), Ipsen Pharma (France), Arbor Pharmaceuticals (US), Tolmar Pharmaceuticals, Inc. (US), GP Pharm (Spain), Debiopharm (Switzerland), DAEWOONG PHARMACEUTICAL CO.,LTD (South Korea), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), Endo International plc (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US) |
|
Market Opportunities |
|
Central Precocious Puberty (CPP) Treatment Market Dynamics
Drivers
- Increasing prevalence of hormonal disorders
The rising prevalence of hormonal disorders is estimated to influence the market's growth rate. Along with this, the growing incidences of obesity will influence the market dynamics during the forecast period.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of central precocious puberty (CPP) treatment market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the central precocious puberty (CPP) treatment market. Additionally, high disposable income and increase in the demand for disease-specific treatments will result in the expansion of central precocious puberty (CPP) treatment market. Along with this, rising use of radiation or chemotherapy for treating cancer and sedentary lifestyle of people will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for growth in the central precocious puberty (CPP) treatment market. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the central precocious puberty (CPP) treatment market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the central precocious puberty (CPP) treatment market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This central precocious puberty (CPP) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the central precocious puberty (CPP) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
One in every 5,000 to 10,000 girls suffers from central precocious puberty. Although the prevalence of the illness is unclear in boys, it is less prevalent in boys.
Central precocious puberty (CPP) treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Central Precocious Puberty (CPP) Treatment Market
The COVID-19 outbreak and subsequent lockdown in different nations had an impact on enterprises in all areas, including private healthcare. Due to heavy lockdown in certain places, the COVID-19 pandemic had disrupted the whole healthcare supply chain. The COVID-19 outbreak has had a three-fold influence on the economy of different countries worldwide: directly influencing production and demand, disrupting distribution routes, and having a financial impact on corporations and financial markets. Due to a decline in the supply of raw materials and pharmaceutical medications by manufacturing businesses linked with central precocious puberty, the impact of the COVID-19 pandemic is likely to hinder the growth of the global central precocious puberty market during the forecast period.
Global Central Precocious Puberty (CPP) Treatment Market Scope
The central precocious puberty (CPP) treatment market is segmented on the basis of type, month, route of administration, gender, diagnosis, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Medication
Long-acting Analogs of Gnrh (Gonadotrophin-Releasing Hormones)
- Leuprolide Acetate
- Triptoreline
- Histrelin Acetate
- Others
Adjunctive Treatments
- Surgery
Diagnosis
- Blood tests
- MRI
- CT scans
- X-rays
Month
- 1-Month
- 2-Month
- 6-Month
- Others
Route of Administration
- Parenteral
Subcutaneous
Intramuscular
Others
- Implants
- Oral
- Others
Gender
- Girls
- Boys
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Central Precocious Puberty (CPP) Treatment Market Regional Analysis/Insights
The Central precocious puberty (CPP) treatment market is analysed and market size insights and trends are provided by country, type, month, route of administration, gender, diagnosis, end-users and distribution channel as referenced above.
The countries covered in the Central precocious puberty (CPP) treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
L'Amérique du Nord domine le marché central du traitement de la puberté précoce (CPP) en raison de l'infrastructure de soins de santé bien établie dans cette région. De plus, l'intérêt croissant des principaux acteurs clés pour les nouvelles technologies propulsera davantage le taux de croissance du marché dans cette région.
L’Asie-Pacifique devrait connaître une croissance au cours de la période de prévision de 2022 à 2029 en raison de l’incidence croissante de l’obésité et de l’augmentation des dépenses de santé dans cette région.
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du traitement de la puberté précoce centrale (CPP)
Le paysage concurrentiel du marché du traitement de la puberté précoce centrale (CPP) fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination de l'application. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché du traitement de la puberté précoce centrale (CPP).
Certains des principaux acteurs opérant sur le marché central du traitement de la puberté précoce (CPP) sont :
- Sanofi (France)
- Pfizer Inc. (États-Unis)
- GlaxoSmithKline plc (Royaume-Uni)
- Novartis SA (Suisse)
- AbbVie Inc. (États-Unis)
- F. Hoffmann-La Roche SA (Suisse)
- Mylan NV (États-Unis)
- Teva Pharmaceutical Industries Ltd. (Irlande)
- Ipsen Pharma (France)
- Arbor Pharmaceuticals (États-Unis)
- Tolmar Pharmaceuticals, Inc. (États-Unis)
- GP Pharm (Espagne)
- Debiopharm (Suisse)
- DAEWOONG PHARMACEUTICAL CO., LTD (Corée du Sud)
- Sun Pharmaceutical Industries Ltd. (Inde)
- Takeda Pharmaceutical Company Limited (Japon)
- Endo International plc (Irlande)
- AstraZeneca (Royaume-Uni)
- Johnson & Johnson Private Limited (États-Unis)
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 MARKET MONTH COVERAGE GRID
2.8 TYPE OF CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT LIFELINE CURVE
2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.1 DBMR MARKET POSITION GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 EPIDEMIOLOGY
6 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: REGULATIONS
7 ASSUMPTIONS
7.1 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE
7.2 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH
7.3 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.4 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER
7.5 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER
7.6 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 GROWING PREVALENCE OF HORMONAL DISORDERS
8.1.2 INCREASING PREVALENCE OF OBESITY
8.1.3 INCREASING CASES OF GRANULOSA CELL TUMOURS
8.1.4 INCREASING GLOBAL HEALTHCARE EXPENDITURE
8.1.5 FAVOURABLE GOVERNMENT SUPPORT FOR PRODUCT APPROVAL
8.2 RESTRAINTS
8.2.1 HIGH TREATMENT COSTS
8.2.2 ADVERSE EFFECTS ASSOCIATED WITH DRUG ADMINISTRATION
8.2.3 COMPLICATIONS ASSOCIATED WITH DIAGNOSIS OF CENTRAL PRECOCIOUS PUBERTY
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
8.3.2 PRESENCE OF STRONG PRODUCT PIPELINE
8.3.3 LAUNCH OF AWARENESS CAMPAIGNS
8.3.4 AVAILABILITY OF OFF LABEL DRUGS
8.4 CHALLENGES
8.4.1 EXISTENCE OF ALTERNATIVE TREATMENT METHODS
8.4.2 INADEQUATE REIMBURSEMENT POLICIES
8.4.3 PATENT EXPIRY
9 IMPACT OF COVID-19 PANDEMIC ON THE GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON SUPPLY CHAIN
9.3 IMPACT ON DEMAND
9.4 GOVERNMENT INITIATIVE
9.5 STRATEGIC DECISIONS FOR MANUFACTURERS
9.6 CONCLUSION
10 GLOBAL CENTRAL PRECOCIOUS PUBERTY TREATMENT MARKET, BY TYPE
10.1 OVERVIEW
10.2 MEDICATION
10.2.1 LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES)
10.2.1.1 LEUPROLIDE ACETATE
10.2.1.2 TRIPTORELIN
10.2.1.3 HISTRELIN ACETATE
10.2.1.4 OTHERS
10.2.2 ADJUNCTIVE TREATMENTS
10.2.2.1 AROMATASE INHIBITORS
10.2.2.2 GROWTH HORMONE
10.2.2.3 NONAROMATIZABLE ANABOLIC STEROIDS
10.3 SURGERY
11 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH
11.1 OVERVIEW
11.2 1- MONTH
11.3 3- MONTH
11.4 6- MONTH
11.5 OTHERS
12 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 PARENTERAL
12.2.1 SUBCUTANEOUS
12.2.2 INTRAMUSCULAR
12.2.3 OTHERS
12.3 ORAL
12.4 IMPLANTS
12.5 OTHERS
13 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER
13.1 OVERVIEW
13.2 GIRLS
13.3 BOYS
14 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOMECARE
14.5 OTHERS
15 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 HOSPITAL PHARMACIES
15.4 RETAIL PHARMACIES
15.5 ONLINE PHARMACIES
15.6 OTHERS
16 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GEOGRAPHY
16.1 OVERVIEW
16.2 NORTH AMERICA
16.2.1 U.S.
16.2.2 CANADA
16.2.3 MEXICO
16.3 EUROPE
16.3.1 GERMANY
16.3.2 FRANCE
16.3.3 U.K
16.3.4 ITALY
16.3.5 NETHERLANDS
16.3.6 SPAIN
16.3.7 RUSSIA
16.3.8 SWITZERLAND
16.3.9 TURKEY
16.3.10 AUSTRIA
16.3.11 NORWAY
16.3.12 HUNGARY
16.3.13 LITHUANIA
16.3.14 IRELAND
16.3.15 POLAND
16.3.16 REST OF EUROPE
16.4 ASIA-PACIFIC
16.4.1 JAPAN
16.4.2 CHINA
16.4.3 AUSTRALIA
16.4.4 SOUTH KOREA
16.4.5 INDIA
16.4.6 SINGAPORE
16.4.7 MALAYSIA
16.4.8 THAILAND
16.4.9 INDONESIA
16.4.10 PHILIPPINES
16.4.11 VIETNAM
16.4.12 REST OF ASIA-PACIFIC
16.5 SOUTH AMERICA
16.5.1 BRAZIL
16.5.2 ARGENTINA
16.5.3 PERU
16.5.4 REST OF SOUTH AMERICA
16.6 MIDDLE EAST & AFRICA
16.6.1 SAUDI ARABIA
16.6.2 SOUTH AFRICA
16.6.3 UAE
16.6.4 ISRAEL
16.6.5 EGYPT
16.6.6 KUWAIT
16.6.7 REST OF MIDDLE EAST & AFRICA
17 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18 COMPANY PROFILES
18.1 ABBVIE INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 ENDO INTERNATIONAL PLC
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 DAEWOONG PHARMACEUTICAL CO.,LTD
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPNAY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 IPSEN PHARMA
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENTS
18.6 ARBOR PHARMACEUTICALS
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENT
18.7 ASTRAZENECA
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 SANOFI
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 DEBIOPHARM
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENTS
18.11 GP PHARM
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 MYLAN N.V.
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 PFIZER INC.
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 TEVA PHARMACEUTICAL USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.15 TOLMAR PHARMACEUTICALS, INC.
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
18.16 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
Liste des tableaux
LIST OF TABLES
TABLE 1 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 GENERIC DRUGS FOR CENTRAL PRECOCIOUS PUBERTY
TABLE 3 MEDICINES SUBJECTED TO PATENT EXPIRY
TABLE 4 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE, 2019-2027 (EURO MILLION)
TABLE 5 GLOBAL MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 6 GLOBAL MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 7 GLOBAL LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 8 GLOBAL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 9 GLOBAL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 10 GLOBAL TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 11 GLOBAL TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 12 GLOBAL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 13 GLOBAL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 14 GLOBAL ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 15 GLOBAL SURGERIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 16 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH, 2019-2027 (EURO MILLION)
TABLE 17 GLOBAL 1- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 18 GLOBAL 3- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 19 GLOBAL 6- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 20 GLOBAL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 21 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (EURO MILLION)
TABLE 22 GLOBAL PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 23 GLOBAL PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 24 GLOBAL ORAL IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 25 GLOBAL IMPLANT IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 26 GLOBAL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 27 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER, 2019-2027 (EURO MILLION)
TABLE 28 GLOBAL GIRLS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 29 GLOBAL BOYS IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 30 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER, 2019-2027 (EURO MILLION)
TABLE 31 GLOBAL HOSPITALS IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 32 GLOBAL SPECILATY CLINICS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 33 GLOBAL HOME CARE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 34 GLOBAL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 35 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (EURO MILLION)
TABLE 36 GLOBAL DIRECT TENDER IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 37 GLOBAL HOSPITAL PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 38 GLOBAL RETAIL PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 39 GLOBAL ONLINE PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 40 GLOBAL OTHERS IN CNETRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2018-2027 (EURO MILLION)
TABLE 41 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2018-2027 (EURO MILLION)
TABLE 42 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)
TABLE 43 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 44 NORTH AMERICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 45 NORTH AMERICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 46 NORTH AMERICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 47 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 48 NORTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 49 NORTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 50 NORTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 51 NORTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 52 NORTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 53 NORTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 54 NORTH AMERICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 55 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 56 NORTH AMERICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 57 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 58 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 59 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 60 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 61 U.S. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 62 U.S. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 63 U.S. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 64 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 65 U.S. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 66 U.S. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 67 U.S. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 68 U.S. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 69 U.S. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 70 U.S. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 71 U.S. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 72 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 73 U.S. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 74 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 75 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 76 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 77 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 78 CANADA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 79 CANADA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 80 CANADA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 81 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 82 CANADA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 83 CANADA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 84 CANADA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 85 CANADA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 86 CANADA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 87 CANADA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 88 CANADA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 89 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 90 CANADA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 91 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 92 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 93 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 94 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 95 MEXICO MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 96 MEXICO LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 97 MEXICO ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 98 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 99 MEXICO LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 100 MEXICO LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 101 MEXICO HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 102 MEXICO HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 103 MEXICO TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 104 MEXICO TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 105 MEXICO OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 106 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 107 MEXICO PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 108 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 109 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 110 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 111 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)
TABLE 112 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 113 EUROPE MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 114 EUROPE LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 115 EUROPE ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 116 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 117 EUROPE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 118 EUROPE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 119 EUROPE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 120 EUROPE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 121 EUROPE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 122 EUROPE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 123 EUROPE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 124 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 125 EUROPE PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 126 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 127 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 128 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 129 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 130 GERMANY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 131 GERMANY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 132 GERMANY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 133 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 134 GERMANY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 135 GERMANY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 136 GERMANY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 137 GERMANY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 138 GERMANY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 139 GERMANY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 140 GERMANY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 141 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 142 GERMANY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 143 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 144 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 145 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 146 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 147 FRANCE MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 148 FRANCE LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 149 FRANCE ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 150 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 151 FRANCE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 152 FRANCE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 153 FRANCE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 154 FRANCE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 155 FRANCE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 156 FRANCE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 157 FRANCE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 158 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 159 FRANCE PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 160 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 161 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 162 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 163 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 164 U.K. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 165 U.K. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 166 U.K. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 167 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 168 U.K. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 169 U.K. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 170 U.K. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 171 U.K. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 172 U.K. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 173 U.K. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 174 U.K. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 175 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 176 U.K. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 177 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 178 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 179 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 180 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 181 ITALY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 182 ITALY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 183 ITALY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 184 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 185 ITALY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 186 ITALY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 187 ITALY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 188 ITALY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 189 ITALY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 190 ITALY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 191 ITALY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 192 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 193 ITALY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 194 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 195 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 196 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 197 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 198 NETHERLANDS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 199 NETHERLANDS LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 200 NETHERLANDS ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 201 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 202 NETHERLANDS LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 203 NETHERLANDS LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 204 NETHERLANDS HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 205 NETHERLANDS HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 206 NETHERLANDS TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 207 NETHERLANDS TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 208 NETHERLANDS OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 209 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 210 NETHERLANDS PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 211 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 212 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 213 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 214 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 215 SPAIN MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 216 SPAIN LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 217 SPAIN ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 218 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 219 SPAIN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 220 SPAIN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 221 SPAIN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 222 SPAIN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 223 SPAIN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 224 SPAIN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 225 SPAIN OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 226 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 227 SPAIN PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 228 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 229 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 230 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 231 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 232 RUSSIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 233 RUSSIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 234 RUSSIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 235 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 236 RUSSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 237 RUSSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 238 RUSSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 239 RUSSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 240 RUSSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 241 RUSSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 242 RUSSIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 243 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 244 RUSSIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 245 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 246 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 247 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 248 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 249 SWITZERLAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 250 SWITZERLAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 251 SWITZERLAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 252 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 253 SWITZERLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 254 SWITZERLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 255 SWITZERLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 256 SWITZERLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 257 SWITZERLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 258 SWITZERLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 259 SWITZERLAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 260 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 261 SWITZERLAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 262 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 263 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 264 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 265 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 266 TURKEY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 267 TURKEY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 268 TURKEY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 269 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 270 TURKEY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 271 TURKEY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 272 TURKEY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 273 TURKEY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 274 TURKEY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 275 TURKEY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 276 TURKEY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 277 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 278 TURKEY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 279 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 280 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 281 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 282 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 283 AUSTRIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 284 AUSTRIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 285 AUSTRIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 286 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 287 AUSTRIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 288 AUSTRIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 289 AUSTRIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 290 AUSTRIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 291 AUSTRIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 292 AUSTRIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 293 AUSTRIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 294 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 295 AUSTRIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 296 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 297 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 298 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 299 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 300 NORWAY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 301 NORWAY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 302 NORWAY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 303 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 304 NORWAY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 305 NORWAY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 306 NORWAY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 307 NORWAY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 308 NORWAY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 309 NORWAY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 310 NORWAY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 311 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 312 NORWAY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 313 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 314 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 315 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 316 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 317 HUNGARY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 318 HUNGARY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 319 HUNGARY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 320 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 321 HUNGARY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 322 HUNGARY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 323 HUNGARY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 324 HUNGARY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 325 HUNGARY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 326 HUNGARY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 327 HUNGARY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 328 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 329 HUNGARY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 330 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 331 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 332 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 333 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 334 LITHUANIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 335 LITHUANIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 336 LITHUANIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 337 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 338 LITHUANIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 339 LITHUANIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 340 LITHUANIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 341 LITHUANIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 342 LITHUANIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 343 LITHUANIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 344 LITHUANIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 345 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 346 LITHUANIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 347 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 348 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 349 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 350 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 351 IRELAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 352 IRELAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 353 IRELAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 354 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 355 IRELAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 356 IRELAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 357 IRELAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 358 IRELAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 359 IRELAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 360 IRELAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 361 IRELAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 362 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 363 IRELAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 364 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 365 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 366 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 367 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 368 POLAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 369 POLAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 370 POLAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 371 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 372 POLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 373 POLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 374 POLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 375 POLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 376 POLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 377 POLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 378 POLAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 379 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 380 POLAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 381 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 382 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 383 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 384 REST OF EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 385 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)
TABLE 386 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 387 ASIA-PACIFIC MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 388 ASIA-PACIFIC LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 389 ASIA-PACIFIC ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 390 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 391 ASIA-PACIFIC LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 392 ASIA-PACIFIC LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 393 ASIA-PACIFIC HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 394 ASIA-PACIFIC HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 395 ASIA-PACIFIC TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 396 ASIA-PACIFIC TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 397 ASIA-PACIFIC OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 398 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 399 ASIA-PACIFIC PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 400 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 401 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 402 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 403 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 404 JAPAN MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 405 JAPAN LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 406 JAPAN ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 407 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 408 JAPAN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 409 JAPAN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 410 JAPAN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 411 JAPAN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 412 JAPAN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 413 JAPAN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 414 JAPAN OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 415 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 416 JAPAN PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 417 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 418 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 419 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 420 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 421 CHINA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 422 CHINA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 423 CHINA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 424 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 425 CHINA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 426 CHINA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 427 CHINA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 428 CHINA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 429 CHINA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 430 CHINA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 431 CHINA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 432 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 433 CHINA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 434 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 435 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 436 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 437 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 438 AUSTRALIA. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 439 AUSTRALIA. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 440 AUSTRALIA. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 441 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 442 AUSTRALIA. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 443 AUSTRALIA. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 444 AUSTRALIA. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 445 AUSTRALIA. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 446 AUSTRALIA. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 447 AUSTRALIA. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 448 AUSTRALIA. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 449 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 450 AUSTRALIA. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 451 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 452 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 453 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 454 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 455 SOUTH KOREA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 456 SOUTH KOREA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 457 SOUTH KOREA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 458 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 459 SOUTH KOREA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 460 SOUTH KOREA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 461 SOUTH KOREA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 462 SOUTH KOREA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 463 SOUTH KOREA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 464 SOUTH KOREA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 465 SOUTH KOREA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 466 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 467 SOUTH KOREA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 468 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 469 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 470 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 471 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 472 INDIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 473 INDIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 474 INDIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 475 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 476 INDIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 477 INDIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 478 INDIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 479 INDIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 480 INDIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 481 INDIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 482 INDIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 483 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 484 INDIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 485 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 486 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 487 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 488 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 489 SINGAPORE MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 490 SINGAPORE LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 491 SINGAPORE ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 492 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 493 SINGAPORE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 494 SINGAPORE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 495 SINGAPORE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 496 SINGAPORE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 497 SINGAPORE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 498 SINGAPORE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 499 SINGAPORE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 500 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 501 SINGAPORE PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 502 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 503 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 504 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 505 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 506 MALAYSIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 507 MALAYSIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 508 MALAYSIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 509 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 510 MALAYSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 511 MALAYSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 512 MALAYSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 513 MALAYSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 514 MALAYSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 515 MALAYSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 516 MALAYSIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 517 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 518 MALAYSIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 519 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 520 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 521 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 522 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 523 THAILAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 524 THAILAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 525 THAILAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 526 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 527 THAILAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 528 THAILAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 529 THAILAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 530 THAILAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 531 THAILAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 532 THAILAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 533 THAILAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 534 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 535 THAILAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 536 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 537 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 538 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 539 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 540 INDONESIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 541 INDONESIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 542 INDONESIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 543 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 544 INDONESIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 545 INDONESIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 546 INDONESIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 547 INDONESIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 548 INDONESIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 549 INDONESIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 550 INDONESIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 551 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 552 INDONESIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 553 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 554 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 555 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 556 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 557 PHILIPPINES MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 558 PHILIPPINES LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 559 PHILIPPINES ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 560 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 561 PHILIPPINES LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 562 PHILIPPINES LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 563 PHILIPPINES HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 564 PHILIPPINES HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 565 PHILIPPINES TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 566 PHILIPPINES TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 567 PHILIPPINES OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 568 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 569 PHILIPPINES PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 570 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 571 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 572 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 573 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 574 VIETNAM MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 575 VIETNAM LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 576 VIETNAM ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 577 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 578 VIETNAM LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 579 VIETNAM LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 580 VIETNAM HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 581 VIETNAM HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 582 VIETNAM TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 583 VIETNAM TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 584 VIETNAM OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 585 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 586 VIETNAM PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 587 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 588 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 589 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 590 REST OF ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 591 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)
TABLE 592 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 593 SOUTH AMERICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 594 SOUTH AMERICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 595 SOUTH AMERICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 596 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 597 SOUTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 598 SOUTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 599 SOUTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 600 SOUTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 601 SOUTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 602 SOUTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 603 SOUTH AMERICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 604 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 605 SOUTH AMERICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 606 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 607 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 608 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 609 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 610 BRAZIL MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 611 BRAZIL LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 612 BRAZIL ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 613 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 614 BRAZIL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 615 BRAZIL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 616 BRAZIL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 617 BRAZIL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 618 BRAZIL TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 619 BRAZIL TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 620 BRAZIL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 621 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 622 BRAZIL PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 623 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 624 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 625 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 626 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 627 ARGENTINA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 628 ARGENTINA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 629 ARGENTINA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 630 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 631 ARGENTINA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 632 ARGENTINA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 633 ARGENTINA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 634 ARGENTINA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 635 ARGENTINA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 636 ARGENTINA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 637 ARGENTINA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 638 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 639 ARGENTINA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 640 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 641 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 642 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 643 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 644 PERU. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 645 PERU. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 646 PERU. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 647 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 648 PERU. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 649 PERU. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 650 PERU. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 651 PERU. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 652 PERU. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 653 PERU. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 654 PERU. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 655 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 656 PERU. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 657 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 658 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 659 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 660 REST OF SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 661 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)
TABLE 662 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 663 MIDDLE EAST & AFRICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 664 MIDDLE EAST & AFRICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 665 MIDDLE EAST & AFRICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 666 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 667 MIDDLE EAST & AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 668 MIDDLE EAST & AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 669 MIDDLE EAST & AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 670 MIDDLE EAST & AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 671 MIDDLE EAST & AFRICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 672 MIDDLE EAST & AFRICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 673 MIDDLE EAST & AFRICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 674 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 675 MIDDLE EAST & AFRICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 676 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 677 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 678 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 679 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 680 SAUDI ARABIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 681 SAUDI ARABIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 682 SAUDI ARABIAADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 683 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 684 SAUDI ARABIALEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 685 SAUDI ARABIALEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 686 SAUDI ARABIAHISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 687 SAUDI ARABIAHISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 688 SAUDI ARABIATRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 689 SAUDI ARABIATRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 690 SAUDI ARABIAOTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 691 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 692 SAUDI ARABIAPARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 693 SAUDI ARABIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 694 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 695 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 696 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 697 SOUTH AFRICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 698 SOUTH AFRICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 699 SOUTH AFRICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 700 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 701 SOUTH AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 702 SOUTH AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 703 SOUTH AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 704 SOUTH AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 705 SOUTH AFRICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 706 SOUTH AFRICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 707 SOUTH AFRICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 708 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 709 SOUTH AFRICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 710 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 711 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 712 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 713 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 714 UAE. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 715 UAE. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 716 UAE. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 717 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 718 UAE. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 719 UAE. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 720 UAE. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 721 UAE. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 722 UAE. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 723 UAE. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 724 UAE. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 725 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 726 UAE. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 727 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 728 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 729 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 730 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 731 ISRAEL MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 732 ISRAEL LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 733 ISRAEL ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 734 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 735 ISRAEL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 736 ISRAEL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 737 ISRAEL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 738 ISRAEL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 739 ISRAELTRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 740 ISRAELTRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 741 ISRAEL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 742 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 743 ISRAEL PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 744 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 745 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 746 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 747 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 748 EGYPT MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 749 EGYPT LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 750 EGYPT ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 751 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 752 EGYPT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 753 EGYPT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 754 EGYPT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 755 EGYPT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 756 EGYPT TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 757 EGYPT TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 758 EGYPT OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 759 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 760 EGYPT PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 761 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 762 EGYPTCENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 763 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 764 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 765 KUWAIT MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 766 KUWAIT LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 767 KUWAIT ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 768 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 769 KUWAIT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 770 KUWAIT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 771 KUWAIT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 772 KUWAIT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 773 KUWAIT TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 774 KUWAIT TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 775 KUWAIT OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 776 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 777 KUWAIT PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 778 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 779 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 780 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 781 REST OF MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
Liste des figures
LIST OF FIGURES
FIGURE 1 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: MARKET MONTH COVERAGE GRID
FIGURE 8 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 9 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 10 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS THE FASTEST GROWING REGION IN THE GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 13 GROWING PREVALENCE OF HORMONAL DISORDERS AND FAVORABLE GOVERNMENT SUPPORT FOR PRODUCT APPROVAL ARE DRIVING THE GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 14 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET IN 2020 & 2027
FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING REGION IN GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET
FIGURE 17 PER CAPITA HEALTHCARE EXPENDITURE, IN 2018 (USD)
FIGURE 18 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY TYPE, 2019
FIGURE 19 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY TYPE, 2019-2027 (EURO MILLION)
FIGURE 20 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 21 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY MONTH, 2019
FIGURE 23 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY MONTH, 2019-2027 (EURO MILLION)
FIGURE 24 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY MONTH, CAGR (2020-2027)
FIGURE 25 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY MONTH, LIFELINE CURVE
FIGURE 26 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 27 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (EURO MILLION)
FIGURE 28 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 29 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY GENDER, 2019
FIGURE 31 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY GENDER, 2019-2027 (EURO MILLION)
FIGURE 32 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY GENDER, CAGR (2020-2027)
FIGURE 33 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 34 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY END USER, 2019
FIGURE 35 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY END USER, 2019-2027 (EURO MILLION)
FIGURE 36 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY END USER, CAGR (2020-2027)
FIGURE 37 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 39 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (EURO MILLION)
FIGURE 40 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 41 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 43 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY REGION (2019)
FIGURE 44 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY REGION (2020 & 2027)
FIGURE 45 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY REGION (2019 & 2027)
FIGURE 46 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 47 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 48 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 49 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 50 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 51 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 52 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 53 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 54 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 55 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 56 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 57 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 58 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 59 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 60 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 61 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 62 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 63 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 64 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 65 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 66 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 67 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 68 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 69 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 70 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 71 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 72 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY SHARE 2019 (%)
FIGURE 73 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY SHARE 2019 (%)
FIGURE 74 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY SHARE 2019 (%)
FIGURE 75 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY SHARE 2019 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
